Introduction
Significant tricuspid regurgitation (TR) is a common condition affecting more than 2% of individuals over the age of 75 years [1] . In the overwhelming majority of cases tricuspid regurgitation develops secondarily. It is the result of incomplete leaflet coaptation caused by tricuspid annular dilatation and/or leaflet tethering due to right ventricular dilatation. Progressive volume overload of the right ventricle promotes a vicious circle characterized by further dilatation of right ventricle, tricuspid annulus and right atrium, which promotes further worsening of TR. Frequently, patients presenting with significant TR also suffer from atrial fibrillation, which may contribute to further annular dilatation. Long-standing TR, specifically in the setting of increased pulmonary pressures, can promote irreversible structural right ventricular, tricuspid annular and right atrial remodelling. It is associated with impaired prognosis in heart failure with preserved as well as reduced ejection fraction [2, 3] . An increasing body of evidence also relates moderate/severe TR to an increased mortality risk, which is independent of pulmonary pressures or right ventricular (RV) function [4, 5] .
The concept of tricuspid valve repair has been well recognized in patients with concomitant left-sided valve disease where additive restrictive tricuspid ring reduction is recommended in patients with concomitant TR or annular remodelling undergoing left-sided valve surgery. In contrast, surgical procedures for isolated TR are associated with a significant shortterm mortality, ranging from 5% to 15%, and have G. Goliasch, MD, PhD · J. Mascherbauer, MD ( ) Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria Julia.mascherbauer@meduniwien.ac.at yet not been shown to improve symptoms or survival [6] [7] [8] . By applying transcatheter techniques morbidity-related conditions, such as cardiopulmonary bypass, sternotomy, pericardiotomy and intubation are avoided, which may significantly improve RV regeneration as well as the perioperative course. Tricuspid valve repair represents a possible way to reduce the burden of TR in patients under guideline-directed medical therapy (GDT) and might add a valuable therapeutic option to decrease the independent driving force of TR. An increasing number of devices ( Fig. 1 ), studies and registries are currently investigating the potential role of transcatheter repair to reduce the burden of TR. Early results show excellent feasibility, low periprocedural mortality and beneficiary effects with respect to functional capacity and quality of life.
Transcatheter repair in tricuspid regurgitation
The MitraClip system (Abbott Vascular, Chicago, IL, USA) was first established for the percutaneous treatment of mitral regurgitation with extensive operator experiences as well as widespread availability. For several years it has also been used off-label for tricuspid repair in high-risk patients ( Fig. 2a-d) . Recently, the system has been adapted for the specific treatment of the tricuspid valve (TriClip), where one or more clips are used to approximate the anterior and septal leaflets resulting in a bicuspidization of the tricuspid valve. The best results appear to be obtained by approximating the anterior and/or posterior leaflet to the septal leaflet, which also potentially reduces annular dimensions. Clipping the anteroposterior leaflets is generally avoided in functional TR because it may distort the valve and worsen TR [9] .
Recently, first prospective data regarding the safety and effectiveness of a tricuspid clip therapy have been published in the TRILUMINATE trial [10] . A total of 85 patients with ≥moderate tricuspid regurgitation were enrolled in this prospective, multicenter, singlearm study in 21 sites in Europe and the USA. Tricuspid regurgitation severity was reduced by at least 1 grade at 30 days in 86% of patients. Regarding patient safety, single leaflet attachment occurred in 5 (7%) out of 72 patients. No periprocedural deaths, conversions to surgery, device embolization, myocardial infarction or stroke were observed, confirming the safety of the procedure.
Furthermore, Taramasso et al. investigated the potential benefit of transcatheter tricuspid valve interventions (TTVI, majority were TriClips) over GDT in a propensity score matched population [11] . The authors concluded that TTVI in high-risk patients with symptomatic severe TR compared with medical treatment alone was associated with lower rates of the composite endpoint of death and rehospitalization for heart failure as well as lower all-cause mortality at 1-year follow-up. This notion was further strengthened by the observation that in the interventional group, a significant difference was observed between patients who were treated successfully compared to patients with incomplete TR reduction despite transcatheter intervention. The TTVI patients without a significant reduction in TR shared similar outcomes with the control group, therefore strongly indicating the prognostic importance of TR reduction in affecting outcomes.
At present, most of the interventional experience for treating TR exists for the clip system. There are, however, specific patient groups that do not qual-ify for a TriClip procedure. Patients with increased gradients across the tricuspid valve after previous surgical tricuspid valve repair, patients with massive leaflet tethering preventing leaflet grasping, or other anatomical limitations may require alternative approaches. In patients with previous tricuspid valve repair or bioprosthetic valve replacement, a valvein-valve or valve-in-ring procedure, using a balloonexpandable transcatheter valve appears to be a good alternative in selected cases ( [12] ; Fig. 1 ). Another alternative method currently under investigation is the TricValve (P+F Products + Features GmbH, Vienna, Austria; Fig. 2e ). The TricValve system consists of two self-expandable stent valves that are implanted in a heterotopic position into the inferior and superior vena cava. The procedure is technically simple and can be performed rapidly without interference to cardiac structures. Devices do not interfere with pre-existing pacemaker or defibrillator leads, which might represent a limitation for orthotopic procedures on the tricuspid valve [13] . Particularly with respect to congestion and symptom relief the device may be beneficial in patients without other therapeutic options, while potential mortality benefit data are currently lacking.
Outlook
Despite increasing numbers of tricuspid procedures, isolated tricuspid valve surgery remains infrequent and continues to be associated with one of the highest risks among all cardiac valve procedures in contem- porary surgical practice resulting in a significant proportion of patients with untreated TR. Low-risk transcatheter techniques have emerged to address this unmet clinical need addressing different anatomic targets. Current data have confirmed the feasibility and safety of various tricuspid treatments, whereas large randomized clinical trials are currently missing; however, continuous advancement of transcatheter devices combined with increased operator experience are likely to improve future procedural and clinical outcomes.
